Hydrogenology
Hydrogenology editorial study record

The Effect of 14-Day Consumption of Hydrogen-Rich Water Alleviates Fatigue but Does Not Ameliorate Dyspnea in Long-COVID Patients: A Pilot, Single-Blind, and Randomized, Controlled Trial

Tan Y et al. · Nutrients. 2024;16(10):1529.

HumanH₂-rich waterPublished 2024
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Pilot single-blind randomized placebo-controlled trial

Research topic

Long COVID

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Vaccinated, non-hospitalized adults aged 18–65 with persistent fatigue and dyspnea after COVID-19

Sample

55 recruited; 32 randomized and completed (16 per group)

Duration

14 days

Intervention

Freshly prepared hydrogen-rich water, 500 mL in the morning and 500 mL in the evening, consumed within 10 minutes

Hydrogen form

H₂ dissolved in water — H₂ only, not Brown’s gas.

H₂ specification

1,600 ppb dissolved H₂; pH 7.6, oxidation-reduction potential −590 mV and 22 °C reported.

H₂ flow

Not applicable — oral water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

Equal amount of pure placebo water in identical packaging

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Fatigue, dyspnea, 6-minute walk, chair stand, sleep quality and mood scales

Reported result

Compared with placebo, percent changes favored H₂ water for fatigue (p=0.046), 6-minute walk distance (p<0.001), chair-stand performance (p=0.002) and sleep quality (p=0.012). Dyspnea (p=0.556) and mood scores did not differ significantly.

Results-extraction completeness

Methods, full outcome tables, funding and conflict statements checked in the open-access full text; independent risk-of-bias appraisal remains incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Small pilot, single blinding, 14-day intervention, home testing with remote administration, multiple outcomes and a secondary percent-change fatigue finding despite a non-significant group-by-time interaction for the primary FSS model.

Applies directly to

Vaccinated, non-hospitalized adults meeting this study’s Long COVID criteria; not hospitalized or medically complex populations.

Preliminary appraisal framework

Cochrane RoB 2 · parallel randomized trial · headline fatigue result

Preliminary risk-of-bias status

High risk — preliminary for the headline fatigue interpretation

Appraisal rationale

Single blinding, staff administering home assessments knew allocation, and the highlighted fatigue finding comes from a secondary percent-change analysis although the primary group-by-time interaction for FSS was not significant.

Appraisal domains

Some concerns — Excel random-number generation is described; allocation concealment is not. · Some concerns — participants were blinded, but assessment staff knew group assignment. · Low concern — all 32 randomized participants completed the study. · High risk for subjective fatigue — remotely administered FSS with assessors aware of allocation. · High risk for the headline fatigue result — emphasis on a secondary percent-change analysis despite a non-significant primary interaction.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 38794767 · DOI: 10.3390/nu16101529

Publisher access

Open-access publisher and PMC full texts are available.

Extraction basis

Open-access publisher full text, PMC record and PubMed bibliographic record.

Record revision

2026-08-10